Terns Pharmaceuticals, Inc. (TERN) Income from Non-Controlling Interests (2020)
Terns Pharmaceuticals (TERN) reported Income from Non-Controlling Interests of -$128000.0 for Q3 2020, up 18.47% quarter-over-quarter from -$157000.0 in Q2 2020.
Terns Pharmaceuticals, Inc. (TERN) Income from Non-Controlling Interests (2020) Analysis & Trends
Terns Pharmaceuticals has reported Income from Non-Controlling Interests for 1 years, with the latest figure at -$128000.0 in Q3 2020.
- For the quarter ending Q3 2020, Income from Non-Controlling Interests changed N/A year-over-year to -$128000.0; the trailing twelve-month figure through Jun 2021 stood at -$285000.0 (changed N/A YoY), and the FY2020 full-year result was -$518000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q3 2020 stood at -$128000.0, up from -$157000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$128000.0 in Q3 2020, with the low at -$205000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | TERN | 4.93 Bn | 3.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -128,000.00 |
| Jun 30, 2020 | -157,000.00 |
| Mar 31, 2020 | -205,000.00 |